Skip to main content

Advertisement

SpringerLink
Log in

In vitro efficacy and fungicidal activity of voriconazole againstAspergillus andFusarium species

  • Note
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

Twenty-nineAspergillus isolates and 25Fusarium isolates underwent in vitro antifungal susceptibility testing by a broth macrodilution procedure adapted from the National Committee for Clinical Laboratory Standards guidelines. The MIC50s of both voriconazole and amphotericin B were 0.5 μg/ml and 1 μg/ml against species ofAspergillus andFusarium, respectively, while the MIC90s of both agents were 1 and 2 μg/ml. Voriconazole was more active in vitro than amphotericin B: the geometric mean MICs of voriconazole and amphotericin B againstAspergillus spp. were 0.36 μg/ml and 0.64 μg/ml, respectively. Voriconazole also demonstrated fungicidal activity againstAspergillus spp., with 86% (24/29) of isolates exhibiting minimum lethal concentrations of ≤4 μg/ml.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Anaissie E, Kantarjian H, Ro H, Hopfer R, Rolston K, Fainstein V, Bodey G: The emerging role ofFusarium infections in patients with cancer. Medicine (1988) 67:77–83

    Google Scholar 

  2. Denning DW, Stevens DA: Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Review of Infectious Diseases (1990) 12:1147–1201

    Google Scholar 

  3. Sekhon AS, Padhye AA, Gurg AK, Ahmad H, Moledina N: In vitro sensitivity of medically significantFusarium species to various antimycotics. Chemotherapy (1994) 40:239–244

    Google Scholar 

  4. Barry AL, Brown SD: In vitro studies of two triazole antifungal agents (voriconazole [UK-109.496] and fluconazole) againstCandida species. Antimicrobial Agents and Chemotherapy (1996) 40:1948–1949

    Google Scholar 

  5. Belanger P, Nast C, Fratti R, Sanati H, Ghannoum M: Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistantCandida species. Antimicrobial Agents and Chemotherapy (1997) 41:1840–1842

    Google Scholar 

  6. Nguyen MH, Yu YC: In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistantCryptococcus neoformans isolates. Antimicrobial Agents and Chemotherapy (1998) 42:471–472

    Google Scholar 

  7. Ruhnke M, Schmidt-Westhausen A, Trautmann M: In vitro activities of voriconazole (UK-109,496) against fluconazolesusceptible and -resistantCandida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy (1997) 41:575–577

    Google Scholar 

  8. Murphy M, Bernard EM, Ishimaru T, Armstrong D: Activity of voriconazole (UK-109,496) against clinical isolates ofAspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrobial Agents and Chemotherapy (1997) 41:696–698

    Google Scholar 

  9. Radford SA, Johnson EM, Warnock DW: In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mould pathogens. Antimicrobial Agents and Chemotherapy (1997) 41:841–843

    Google Scholar 

  10. Espinel-Ingroff A, Bartlett M, Bowden R, Chiu NX, Cooper C, Fothergill A, McGinnis MR, Menezes P, Messer SA, Nelson PW, Odds FC, Pasareil L, Peter J, Pfaller MA, Rex JH, Rinaldi MG, Shankland GS, Walsh TJ, Weitzman I: Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. Journal of Clinical Microbiology (1997) 35:139–143

    Google Scholar 

  11. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Tentative standard M27-T. NCCLS, Villanova, PA (1995)

    Google Scholar 

  12. George D, Miniter P, Andriole VT: Efficacy of UK-109496, a new triazole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrobial Agents and Chemotherapy (1996) 40:86–91

    Google Scholar 

  13. Nguyen MH, Clancy CJ, Yu VL, Yu YC, Norris AJ, Snydman DA, Sutton DA, Rinaldi MG: Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients withCandida fungemia. Journal of Infectious Diseases (1998) 177:425–430

    Google Scholar 

  14. McGinnis MR, Pasareil L, Sutton DA, Fothergill AW, Cooper CR, Rinaldi MG: In vitro evaluation of voriconazole against some clinically important fungi. Antimicrobial Agents and Chemotherapy (1997) 41:1832–1834

    Google Scholar 

  15. Denning DW, Venkateswarlu K, Oakley KL, Oakely MJ, Anderson MJ, Manning NJ, Stevens DA, Warnock DW, Kelly SL: Itraconazole resistance inAspergilllus fumigatus. Antimicrobial Agents and Chemotherapy (1997) 41:1364–1368

    Google Scholar 

  16. Walsh TJ, Melchor GP, Rinaldi MG, Lecciones J, McGough DA, Kelly V, Lee J, Callender D, Rubin M, Pizzo PA:Trichosporon beigelli, an emerging pathogen resistant to amphotericin B. Journal of Clinical Microbiology (1990) 28:1616–1622

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Florida, College of Medicine and VA Medical Center, JHMHC, PO Box 100277, 32610, Gainesville, FL, USA

    C. J. Clancy & M. H. Nguyen

Authors
  1. C. J. Clancy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. H. Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clancy, C.J., Nguyen, M.H. In vitro efficacy and fungicidal activity of voriconazole againstAspergillus andFusarium species. Eur. J. Clin. Microbiol. Infect. Dis. 17, 573–575 (1998). https://doi.org/10.1007/BF01708622

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01708622

Keywords

Search

Navigation